https://orcid.org/0000-0002-2226-0239
Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Daniele Roberto Giacobbe, Vincenzo Di Pilato, Ilias Karaiskos, Tommaso Giani, Anna Marchese, Gian Maria Rossolini & Matteo Bassetti. (2023) Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades. Annals of Medicine 55:1, pages 101-113.
Read now
Read now
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki & Effie Scoulica. (2023) In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae isolates. Journal of Chemotherapy 35:7, pages 596-600.
Read now
Read now
Abdollah Ardebili, Ahdieh Izanloo & Mostafa Rastegar. (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?. Expert Review of Anti-infective Therapy 21:4, pages 387-429.
Read now
Read now
Articles from other publishers (15)
Vincenzo Di Pilato, Luigi Principe, Lilia Andriani, Noemi Aiezza, Marco Coppi, Silvia Ricci, Tommaso Giani, Francesco Luzzaro & Gian Maria Rossolini. (2023) Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam. Clinical Microbiology and Infection 29:4, pages 537.e1-537.e8.
Crossref
Crossref
Varshaa Arer & Debasish Kar. (2023) Biochemical exploration of β-lactamase inhibitors. Frontiers in Genetics 13.
Crossref
Crossref
Natalia G. Vallianou, Alexandros Skourtis, Dimitris Kounatidis, Evangelia Margellou, Fotis Panagopoulos, Eleni Geladari, Angelos Evangelopoulos & Edison Jahaj. (2023) The Role of the Respiratory Microbiome in the Pathogenesis of Aspiration Pneumonia: Implications for Diagnosis and Potential Therapeutic Choices. Antibiotics 12:1, pages 140.
Crossref
Crossref
Matteo Bassetti, Antonio Vena, Laura Labate & Daniele R. Giacobbe. (2022) Empirical antibiotic therapy for difficult-to-treat Gram-negative infections: when, how, and how long?. Current Opinion in Infectious Diseases 35:6, pages 568-574.
Crossref
Crossref
Helen Giamarellou & Ilias Karaiskos. (2022) Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients. Antibiotics 11:8, pages 1009.
Crossref
Crossref
Silvana Alfei & Anna Maria Schito. (2022) β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources. Pharmaceuticals 15:4, pages 476.
Crossref
Crossref
Luigi Principe, Tommaso Lupia, Lilia Andriani, Floriana Campanile, Davide Carcione, Silvia Corcione, Francesco De Rosa, Roberto Luzzati, Giacomo Stroffolini, Marina Steyde, Giuliana Decorti & Stefano Di Bella. (2022) Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals 15:4, pages 463.
Crossref
Crossref
Silvana Alfei & Guendalina Zuccari. (2022) Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production. Pharmaceuticals 15:3, pages 384.
Crossref
Crossref
Marta Hernández-García, María García-Castillo, Patricia Ruiz-Garbajosa, Germán Bou, María Siller-Ruiz, Cristina Pitart, Irene Gracia-Ahufinger, Xavier Mulet, Álvaro Pascual, Nuria Tormo & Rafael Cantón. (2022)
In Vitro
Activity of Cefepime-Taniborbactam against Carbapenemase-Producing
Enterobacterales
and Pseudomonas aeruginosa Isolates Recovered in Spain
. Antimicrobial Agents and Chemotherapy 66:3.
Crossref
Crossref
Daniele Roberto Giacobbe, Michele Mirabella, Matteo Rinaldi, Angela Raffaella Losito, Francesca Raffaelli, Filippo Del Puente, Carolina Saffioti, Malgorzata Mikulska, Maddalena Giannella, Pierluigi Viale, Mario Tumbarello & Matteo Bassetti. (2021) Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. Antibiotics 10:12, pages 1554.
Crossref
Crossref
Matteo Bassetti, Antonio Vena, Daniele Roberto Giacobbe & Nadia Castaldo. (2021) Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. Archives of Medical Research 52:8, pages 817-827.
Crossref
Crossref
Nicole Pagani, Silvia Corcione, Tommaso Lupia, Silvia Scabini, Claudia Filippini, Roberto Angilletta, Nour Shbaklo, Simone Mornese Pinna, Renato Romagnoli, Luigi Biancone, Rossana Cavallo, Giovanni Di Perri, Paolo Solidoro, Massimo Boffini & Francesco Giuseppe De Rosa. (2021) Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection in Solid Organ Transplant Recipients: A Single-Center, Retrospective Study. Microorganisms 9:11, pages 2272.
Crossref
Crossref
Davide Carcione, Claudia Siracusa, Adela Sulejmani, Valerio Leoni & Jari Intra. (2021) Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use. Antibiotics 10:8, pages 995.
Crossref
Crossref
Giulia De Angelis, Riccardo Paggi, Thomas J. Lowery, Jessica L. Snyder, Giulia Menchinelli, Maurizio Sanguinetti, Brunella Posteraro & Antonella Mencacci. (2021) Direct Testing for KPC-Mediated Carbapenem Resistance from Blood Samples Using a T2 Magnetic Resonance Based Assay. Antibiotics 10:8, pages 950.
Crossref
Crossref
Roberto Giurazza, Maria Civita Mazza, Roberto Andini, Pasquale Sansone, Maria Caterina Pace & Emanuele Durante-Mangoni. (2021) Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. Life 11:6, pages 519.
Crossref
Crossref